Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.

Feun LG, Li YY, Wu C, Wangpaichitr M, Jones PD, Richman SP, Madrazo B, Kwon D, Garcia-Buitrago M, Martin P, Hosein PJ, Savaraj N.

Cancer. 2019 Jun 28. doi: 10.1002/cncr.32339. [Epub ahead of print]

PMID:
31251403
2.

Optical coherence tomography imaging of melanoma skin cancer.

Rajabi-Estarabadi A, Bittar JM, Zheng C, Nascimento V, Camacho I, Feun LG, Nasiriavanaki M, Kunz M, Nouri K.

Lasers Med Sci. 2019 Mar;34(2):411-420. doi: 10.1007/s10103-018-2696-1. Epub 2018 Dec 11. Review.

PMID:
30539405
3.

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma.

Feun LG, Wangpaichitr M, Li YY, Kwon D, Richman SP, Hosein PJ, Savaraj N.

J Hepatocell Carcinoma. 2018 Jan 12;5:9-15. doi: 10.2147/JHC.S153672. eCollection 2018.

4.

Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation.

Li YY, Wu C, Shah SS, Chen SM, Wangpaichitr M, Kuo MT, Feun LG, Han X, Suarez M, Prince J, Savaraj N.

Mol Oncol. 2017 Dec;11(12):1806-1825. doi: 10.1002/1878-0261.12151. Epub 2017 Nov 16.

5.

Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1α Degradation at the ASS1 promoter for ASS1 Derepression.

Tsai WB, Long Y, Chang JT, Savaraj N, Feun LG, Jung M, Chen HHW, Kuo MT.

Sci Rep. 2017 Sep 7;7(1):10814. doi: 10.1038/s41598-017-11445-0.

6.

Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer.

Wangpaichitr M, Kandemir H, Li YY, Wu C, Nguyen D, Feun LG, Kuo MT, Savaraj N.

Cell Dev Biol. 2017 Jun;6(2). pii: 183. doi: 10.4172/2168-9296.1000183. Epub 2017 Apr 28.

7.

Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy.

Li YY, Feun LG, Thongkum A, Tu CH, Chen SM, Wangpaichitr M, Wu C, Kuo MT, Savaraj N.

Int J Mol Sci. 2017 Jun 19;18(6). pii: E1297. doi: 10.3390/ijms18061297. Review.

8.

Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer.

Wangpaichitr M, Wu C, Li YY, Nguyen DJM, Kandemir H, Shah S, Chen S, Feun LG, Prince JS, Kuo MT, Savaraj N.

Oncotarget. 2017 Jul 25;8(30):49275-49292. doi: 10.18632/oncotarget.17568.

9.

Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy.

Long Y, Tsai WB, Wang D, Hawke DH, Savaraj N, Feun LG, Hung MC, Chen HH, Kuo MT.

Cancer Lett. 2017 Mar 1;388:54-63. doi: 10.1016/j.canlet.2016.11.028. Epub 2016 Nov 30.

PMID:
27913198
10.

Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.

Long Y, Tsai WB, Chang JT, Estecio M, Wangpaichitr M, Savaraj N, Feun LG, Chen HH, Kuo MT.

Oncotarget. 2016 Dec 13;7(50):82658-82670. doi: 10.18632/oncotarget.12308.

11.

BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma.

Li YY, Wu C, Chen SM, Shah SS, Wangpaichitr M, Feun LG, Kuo MT, Suarez M, Prince J, Savaraj N.

Oncotarget. 2016 Apr 5;7(14):17665-80. doi: 10.18632/oncotarget.6882.

12.

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.

Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C.

J Clin Oncol. 2015 Dec 1;33(34):4093-8. doi: 10.1200/JCO.2015.61.6490. Epub 2015 Nov 2.

13.

Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents.

Tsai WB, Long Y, Park JR, Chang JT, Liu H, Rodriguez-Canales J, Savaraj N, Feun LG, Davies MA, Wistuba II, Kuo MT.

Oncogene. 2016 Mar 31;35(13):1632-42. doi: 10.1038/onc.2015.237. Epub 2015 Jun 22.

14.

Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy.

Chen HH, Chen WC, Liang ZD, Tsai WB, Long Y, Aiba I, Fu S, Broaddus R, Liu J, Feun LG, Savaraj N, Kuo MT.

Expert Opin Ther Targets. 2015;19(10):1307-17. doi: 10.1517/14728222.2015.1043269. Epub 2015 May 25. Review.

15.

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.

Savaraj N, Wu C, Li YY, Wangpaichitr M, You M, Bomalaski J, He W, Kuo MT, Feun LG.

Oncotarget. 2015 Mar 20;6(8):6295-309.

16.

Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma.

Wangpaichitr M, Wu C, Bigford G, Theodoropoulos G, You M, Li YY, Verona-Santos J, Feun LG, Nguyen DM, Savaraj N.

Anticancer Res. 2014 Dec;34(12):6991-9.

PMID:
25503125
17.

Arginine deprivation in cancer therapy.

Feun LG, Kuo MT, Savaraj N.

Curr Opin Clin Nutr Metab Care. 2015 Jan;18(1):78-82. doi: 10.1097/MCO.0000000000000122. Review.

PMID:
25474015
18.

Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.

Long Y, Tsai WB, Wangpaichitr M, Tsukamoto T, Savaraj N, Feun LG, Kuo MT.

Mol Cancer Ther. 2013 Nov;12(11):2581-90. doi: 10.1158/1535-7163.MCT-13-0302. Epub 2013 Aug 26.

19.

Arginine deprivation therapy for malignant melanoma.

Yoon JK, Frankel AE, Feun LG, Ekmekcioglu S, Kim KB.

Clin Pharmacol. 2013;5:11-9. doi: 10.2147/CPAA.S37350. Epub 2012 Dec 27.

20.

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.

Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, Sisson W, Jungbluth AA, Bomalaski J, Savaraj N.

Br J Cancer. 2012 Apr 24;106(9):1481-5. doi: 10.1038/bjc.2012.106.

21.

The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells.

Wangpaichitr M, Sullivan EJ, Theodoropoulos G, Wu C, You M, Feun LG, Lampidis TJ, Kuo MT, Savaraj N.

Mol Cancer Ther. 2012 Mar;11(3):604-15. doi: 10.1158/1535-7163.MCT-11-0599. Epub 2012 Jan 16.

22.

Preoperative evaluation for patients with choroidal/ciliary body melanomas: what is necessary?

Wykoff CC, Murray TG, Markoe AM, Feun LG, Schefler AC, Gayer S.

Am J Ophthalmol. 2011 Jun;151(6):921-4. doi: 10.1016/j.ajo.2011.01.050. No abstract available.

PMID:
21616209
23.

Topoisomerase I inhibitors in the treatment of primary CNS malignancies: an update on recent trends.

Sasine JP, Savaraj N, Feun LG.

Anticancer Agents Med Chem. 2010 Nov 1;10(9):683-96. Review.

PMID:
21235438
24.
25.

Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.

Savaraj N, You M, Wu C, Wangpaichitr M, Kuo MT, Feun LG.

Curr Mol Med. 2010 Jun;10(4):405-12. Review.

26.

Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era.

Levi DM, Tzakis AG, Martin P, Nishida S, Island E, Moon J, Selvaggi G, Tekin A, Madrazo BL, Narayanan G, Garcia MT, Feun LG, Tryphonopoulos P, Skartsis N, Livingstone AS.

J Am Coll Surg. 2010 May;210(5):727-34, 735-6. doi: 10.1016/j.jamcollsurg.2010.01.007.

PMID:
20421039
27.
28.

Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.

Feun LG, Marini A, Landy H, Markoe A, Heros D, Robles C, Herrera C, Savaraj N.

J Neurooncol. 2007 Apr;82(2):177-81. Epub 2006 Oct 19.

PMID:
17051317
29.

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.

Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG, Logan TF.

J Clin Oncol. 2005 Oct 20;23(30):7660-8. Erratum in: J Clin Oncol. 2006 Aug 20;24(24):4047.

PMID:
16234528
30.

Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial.

Feun LG, O'Brien C, Molina E, Rodriguez M, Jeffers L, Schiff ER, Marini A, Savaraj N, Ardalan B.

J Cancer Res Clin Oncol. 2003 Jan;129(1):17-20. Epub 2003 Jan 9.

PMID:
12618896
31.

Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma.

Feun LG, Savaraj N, Hurley J, Marini A.

Cancer Invest. 2002;20(3):357-61.

PMID:
12025231
32.

Procollagen-Like Protein as a Molecular Target in the Treatment of Primary Brain Tumor.

Wangpaichitr M, Landy H, Wu CJ, Feun LG, Xu R, Xu J, Savaraj N.

ScientificWorldJournal. 2002 Apr 9;2:125-126. doi: 10.1100/tsw.2002.59. eCollection 2002. No abstract available.

33.
34.

A phase I study of chemoembolization with cisplatin, thiotepa, and lipiodol for primary and metastatic liver cancer.

Feun LG, Reddy KR, Scagnelli T, Yrizarry JM, Guerra JJ, Russell E, Schwartz M, Savaraj N, Livingstone AS, Levi JU, Jeffers LJ, Ardalan B, Schiff ER.

Am J Clin Oncol. 1999 Aug;22(4):375-80.

PMID:
10440193
35.

A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.

Feun LG, Blessing JA, Major FJ, DiSaia PJ, Alvarez RD, Berek JS.

Gynecol Oncol. 1998 Dec;71(3):410-5.

PMID:
9887240
36.

Multidrug-resistant gene expression in small-cell lung cancer.

Savaraj N, Wu CJ, Xu R, Lampidis T, Lai S, Donnelly E, Solomon J, Feun LG.

Am J Clin Oncol. 1997 Aug;20(4):398-403.

PMID:
9256898
37.

Phase II trial of mitoxantrone and cisplatin in advanced non-small-cell lung cancer.

Feun LG, Savaraj N, Solomon J, Liebmann A, Hurley J.

Am J Clin Oncol. 1996 Apr;19(2):190-2.

PMID:
8610648
39.

Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma.

Feun LG, Robinson WA, Savaraj N, Gonzalez R, Liebmann A, Offenhauser K, Clendeninn NJ.

Am J Clin Oncol. 1995 Dec;18(6):488-90.

PMID:
8526190
40.

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.

Meyskens FL Jr, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, Feun LG, Doroshow JH, Flaherty LE, Sondak VK.

J Natl Cancer Inst. 1995 Nov 15;87(22):1710-3. No abstract available.

41.

Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma.

Feun LG, Savaraj N, Moffat F, Robinson D, Liebmann A, Hurley J, Raub WA Jr, Richman SP.

Melanoma Res. 1995 Aug;5(4):273-6.

PMID:
7496164
42.

Oral piritrexim in advanced bladder cancer: an effective drug after progression on MVAC chemotherapy?

Feun LG, Savaraj N, Benedetto P, Waldman S, Collier M, Clendennin NJ.

Am J Clin Oncol. 1994 Oct;17(5):448-51.

PMID:
8092120
43.

A phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer.

Feun LG, Reddy KR, Yrizarry JM, Savaraj N, Guerra JJ Jr, Purser RK, Waldman S, Levi JU, Moffatt F, Morrell L, et al.

Am J Clin Oncol. 1994 Oct;17(5):405-10.

PMID:
8092112
44.

A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma.

Feun LG, Savaraj N, Hung S, Reddy R, Jeffers L, Benedetto P, Livingstone AS, Ardalan B, Levi JU, Parker T, et al.

Am J Clin Oncol. 1994 Oct;17(5):393-5.

PMID:
8092109
45.

The role of steroids in the management of metastatic carcinoma to the brain. A pilot prospective trial.

Wolfson AH, Snodgrass SM, Schwade JG, Markoe AM, Landy H, Feun LG, Sridhar KS, Brandon AH, Rodriguez M, Houdek PV.

Am J Clin Oncol. 1994 Jun;17(3):234-8.

PMID:
8192109
46.

Melanoma in a southeastern Hispanic population.

Feun LG, Raub WA Jr, Duncan RC, Moffat F, Savaraj N, Nemeth A, Markoe A, Trapido E.

Cancer Detect Prev. 1994;18(2):145-52.

PMID:
8025897
47.

Drug resistance in brain tumors.

Feun LG, Savaraj N, Landy HJ.

J Neurooncol. 1994;20(2):165-76. Review.

PMID:
7807193
48.
49.

Visual recovery from radiation-induced optic neuropathy. The role of hyperbaric oxygen therapy.

Borruat FX, Schatz NJ, Glaser JS, Feun LG, Matos L.

J Clin Neuroophthalmol. 1993 Jun;13(2):98-101.

PMID:
8340486
50.

Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy.

Milam AH, Saari JC, Jacobson SG, Lubinski WP, Feun LG, Alexander KR.

Invest Ophthalmol Vis Sci. 1993 Jan;34(1):91-100.

PMID:
8425845

Supplemental Content

Support Center